Exempt Offering Notice · D

Femasys Inc.

FEMYNASDAQEQUITYCurrent

Exempt Offering Notice

Filed Aug 20, 2026Accepted Aug 20, 2026, 4:15 PM EDTFiling CIK 1339005Accession 0000945621-26-001085

View company →Permanent SEC source ↗

Structured filing — D

primary_doc.xml

Open full document ↗

Issuer

Name: FEMASYS INC
CIK: 0001339005
Entity type: Corporation
Jurisdiction: DELAWARE
Phone: 770-500-3910
Street: 3950 JOHNS CREEK COURT
Street (continued): SUITE 100
City: SUWANEE
State / country code: GA
State / country: GEORGIA
Postal code: 30024
Incorporated more than five years ago: true
Previous issuer names: None
Previous EDGAR names: None

Related person 1

First name: Kathy
Last name: Lee-Sepsick
Relationships: Executive Officer · Director
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Related person 2

First name: Dov
Last name: Elefant
Relationships: Executive Officer
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Related person 3

First name: Charles
Last name: Larsen
Relationships: Director
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Related person 4

First name: Alistair
Last name: Milnes
Relationships: Director
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Related person 5

First name: Kenneth
Last name: Eichenbaum
Relationships: Director
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Related person 6

First name: Edward
Middle name: R.
Last name: Uzialko
Relationships: Director
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Related person 7

First name: Jeremy
Last name: Sippos
Relationships: Executive Officer
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Related person 8

First name: John
Last name: Canninng
Relationships: Executive Officer
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Related person 9

First name: Jeffrey
Last name: Mifek
Relationships: Executive Officer
Relationship clarification: [blank]
Street: 3950 Johns Creek Court
Street (continued): Suite 100
City: Suwanee
State / country code: GA
State / country: GEORGIA
Postal code: 30024

Offering

Industry: Biotechnology
Revenue range: Decline to Disclose
Exemption codes: 06b
Amendment: false
First sale date: 2026-08-10
Offering lasts more than one year: false
Equity securities: true
Business combination: false
Business combination clarification: [blank]
Minimum investment accepted: 0
Total offering amount: 30,000,000
Amount sold: 30,000,000
Remaining amount: 0
Amount clarification: See the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 11, 2026.
Non-accredited investors reported: false
Investors already participating: 41

Commissions, fees and proceeds

Sales commissions: 0
Finders’ fees: 0
Commission / fee clarification: [blank]
Gross proceeds used: 0
Use of proceeds clarification: [blank]

Signature authorization

Authorized representative: false

Signature 1

Issuer: FEMASYS INC
Signer: Kathy Lee-Sepsick
Signed: /s/ Kathy Lee-Sepsick
Title: Chief Executive Officer
Date: 2026-08-20

Company context

We are a leading biomedical innovator, addressing significant unmet needs in women’s health worldwide, with a broad patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. We are a U.S. manufacturer that has received global regulatory approvals for its product portfolio worldwide, and its products are currently being commercialized in the U.S. and key international markets. FemaSeed® Intratubal Insemination, a groundbreaking infertility treatment delivering sperm directly to the site of conception, is U.S. FDA-cleared and approved in Europe, United Kingdom (“UK”), Canada, Israel, Australia and New Zealand. A peer-reviewed publication of positive data from its pivotal clinical trial of FemaSeed demonstrated effectiveness and safety with high satisfaction from both patients and practitioners. In August 2025, we announced the introduction of its FemSperm™ Setup Kit, the first in a planned family of products designed to fully enable gynecologists for FemaSeed Intratubal Insemination. The setup kit includes customized components, such as a pre-configured centrifuge to optimize sperm preparation for use with FemaSeed. FemVue®, a companion diagnostic for fallopian tube assessment via ultrasound, is U.S. FDA-cleared and approved in Europe, UK, Canada, Japan, Israel, Australia and New Zealand. FemCerv®, an endocervical tissue sampler for cervical cancer diagnosis, is U.S. FDA-cleared and approved in Europe, UK, Canada, Israel and New Zealan

Current securities

FEMYNASDAQ · EQUITY · Current

Get the free weekly BCS email.